Featured Research

from universities, journals, and other organizations

Deaths reduced with cardiac resynchronization therapy

Date:
February 3, 2011
Source:
Canadian Medical Association Journal
Summary:
Cardiac resynchronization therapy shows major benefit in reducing mortality in people with heart failure when combined with optimal medical therapy or implantable cardioverter defibrillator, according to a new study.

Cardiac resynchronization therapy shows major benefit in reducing mortality in people with heart failure when combined with optimal medical therapy or implantable cardioverter defibrillator, according to a study published in CMAJ (Canadian Medical Association Journal).

Cardiac resynchronization therapy involves pacing from both the left and right ventricles of the heart at the same time to improve efficiency.

Congestive heart failure is a major health issue in Canada, with more 500,000 Canadians affected and 50,000 new cases each year. The death rate after a year in people with the condition ranges from 25% to 50%, depending on severity, and it accounts for more than 100,000 hospital admissions annually.

"The cumulative evidence is now conclusive that the addition of cardiac resynchronization therapy to optimal medical therapy or to implantable defibrillator significantly reduces mortality among patients with mildly symptomatic or advanced heart failure," writes Dr. George Wells, University of Ottawa Heart Institute, with coauthors.

They conclude "cardiac resynchronization therapy may now be extended to a much wider proportion of patients with heart failure, improving long-term outcomes in this growing population."


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. George Wells, Ratika Parkash, Jeffrey S. Healey, Mario Talajic, J. Malcolm Arnold, Shannon Sullivan, Joan Peterson, Elizabeth Yetisir, Patricia Theoret-Patrick, Marilynn Luce and Anthony S.L. Tang. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal, 2011; DOI: 10.1503/cmaj.101685

Cite This Page:

Canadian Medical Association Journal. "Deaths reduced with cardiac resynchronization therapy." ScienceDaily. ScienceDaily, 3 February 2011. <www.sciencedaily.com/releases/2011/01/110131132946.htm>.
Canadian Medical Association Journal. (2011, February 3). Deaths reduced with cardiac resynchronization therapy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/01/110131132946.htm
Canadian Medical Association Journal. "Deaths reduced with cardiac resynchronization therapy." ScienceDaily. www.sciencedaily.com/releases/2011/01/110131132946.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins